The association of glucose metabolism measures and diabetes status with Alzheimer's disease biomarkers of amyloid and tau: A systematic review and meta-analysis.
Amyloid-beta
Cerebrospinal fluid (CSF)
Elderly persons
Fasting blood glucose (FBG)
Glycated hemoglobin (HbA1c)
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Mini Mental Status Examination (MMSE)
Positron emission tomography (PET)
Tau
Type 2 DM mellitus (T2DM)
Journal
Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
23
11
2023
revised:
21
02
2024
accepted:
23
02
2024
pubmed:
1
3
2024
medline:
1
3
2024
entrez:
29
2
2024
Statut:
ppublish
Résumé
Conflicting evidence exists on the relationship between diabetes mellitus (DM) and Alzheimer's disease (AD) biomarkers. Therefore, we conducted a random-effects meta-analysis to evaluate the correlation of glucose metabolism measures (glycated hemoglobin, fasting blood glucose, insulin resistance indices) and DM status with AD biomarkers of amyloid-β and tau measured by positron emission tomography or cerebrospinal fluid. We selected 37 studies from PubMed and Embase, including 11,694 individuals. More impaired glucose metabolism and DM status were associated with higher tau biomarkers (r=0.11[0.03-0.18], p=0.008; I2=68%), but were not associated with amyloid-β biomarkers (r=-0.06[-0.13-0.01], p=0.08; I
Identifiants
pubmed: 38423195
pii: S0149-7634(24)00073-3
doi: 10.1016/j.neubiorev.2024.105604
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105604Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.